Crossmark

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Published Online: 2024-10-18

Published Print: 2024-12

Authors

Carter, Paul J. https://orcid.org/0000-0001-7854-062X
Quarmby, Valerie https://orcid.org/0000-0002-1043-7973
License Information

Text and Data Mining valid from 2024-10-18

Version of Record valid from 2024-10-18
More Information

Article History

Accepted: 10 September 2024

First Online: 18 October 2024

Competing interests

: The authors are current (P.J.C.) or former (V.Q.) employees of Genentech, Inc., which develops and commercializes therapeutics, including antibodies and other proteins.

Document is current